วีดีโอ

Where can i get pdf for this lecture??

thank you professor im going through oral exam you have saved me

I was diagnosed with ITP and was struggling to find a natural solution. Thankfully, I discovered Planet Ayurveda and their amazing products! My platelet count has increased significantly since I started using their supplements.

Thank you for making this video.

New ICI for metastatic cutaneous squamous cell carcinoma: Cosibelimab The US Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor cosibelimab (Unloxcyt; Checkpoint Therapeutics, Inc.) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The programmed death ligand-1 (PD-L1)-blocking antibody is the first and only treatment of its kind approved for advanced CSCC, according to a Checkpoint Therapeutics press release. The FDA approval was based on findings from the multicenter, open-label Study CK-301-101 trial of 109 patients. In that trial, the objective response rate (ORR) was 47% in 78 patients with metastatic CSCC and 48% in 31 patients with locally advanced CSCC. Median duration of response (DOR) in treated patients was not reached in those with metastatic disease and was 17.7 months in those with locally advanced disease, according to the FDA approval notice.

I was diagnosed to have ITP since I was 3. I'm 51 now and still suffering with bruising, headaches, joint pains, fatigue, palpitation. I take prednisone on and off. I detest the side effects. ..

Pls help children whith colon cancer plz they are ding

Durvalumab maintenance therapy up to 2 years approved by FDA in 12/4/24 for Limited Stage Small Cell Lung Cancer (when no progression after induction chemo radiation therapy On Dec. 4, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (LS-SCLC) without disease progression after platinum-based chemotherapy and radiation therapy. The approval marks the most significant shift in care for limited-stage SCLC in decades. FDA officials based their decision on results from the double-blind, randomized, placebo-controlled ADRIATIC clinical trial. The phase 3 study included 730 patients with LS-SCLC whose disease did not progress after current platinum-based chemotherapy and radiation. Investigators enrolled patients with stage I-III LS-SCLC or inoperable stage I/II disease, good performance status, and no progression after first-line chemoradiotherapy. After stratification, participants were randomly assigned in a 1:1:1 manner to receive single-agent durvalumab, durvalumab plus tremelimumab (Imjudo), or placebo. The study’s primary endpoints were overall survival (OS) and progression-free survival. A blinded independent central review assessed the comparison between single-agent durvalumab and placebo. Durvalumab elicited a statistically significant OS improvement compared with placebo, with a hazard ratio (HR) of 0.73 (95% confidence interval [CI], 0.57-0.93; P-value=.0104). The median OS was 55.9 months (95% CI, 37.3 months to not reached) in the durvalumab group compared with 33.4 months (95% CI, 25.5-39.9 months) in the placebo group. In addition, durvalumab had a statistically significant PFS improvement compared with placebo, with an HR of 0.76 (95% CI, 0.61-0.95; P-value=.0161). The median PFS was 16.6 months in the durvalumab group (95% CI, 10.2-28.2 months) and 9.2 months in the placebo group (95% CI, 7.4-12.9 months). Data from the ADRIATIC trial were met with applause when they were presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in June. Experts at the meeting said the results were practice-changing. “This groundbreaking trial sets a new standard of care with consolidative durvalumab following concurrent chemoradiation,” said Lauren Averett Byers, MD, from the University of Texas MD Anderson Cancer Center in Houston, who spoke as a discussant during the meeting. “The next step will be moving beyond one size fits all and moving toward personalized, biomarker-driven approaches for patients with small cell lung cancer.” The most common adverse reactions, which occurred in at least 20% of patients, were pneumonitis or radiation pneumonitis and fatigue. Hypertension was the most common grade 3 or higher adverse event and occurred in about one-third of patients in each group, according to data reported at ASCO 2024.

Nivolumab + AVD prolonged disease free survival when compared with bretuximab vedotin + AVD in Hodgkin’s lymphoma stage III and IV patients. www.nejm.org/doi/10.1056/NEJMoa2405888

Thank you teachear

Thanks Dr. My ferritin level has been above 300 for almost a decade and is now at 600. My doc has never even mentioned it. Should I be concerned and get a second opinion?

Zanidatamb, a bispecific antibody therapy for recurrent/ metastatic HER2 (+) biliary cancer was approved by FDA in November 2024. www.targetedonc.com/view/fda-approves-zanidatamab-in-her2-biliary-tract-cancer

Adding Pembrolizumab to chemo radiation therapy for locally advanced cervical cancer improved overall survival. www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01808-7/abstract

Adjuvant pembrolizumab for 1 yr improved overall survival (doubled to >26 Mon) in High grade urothelial carcinoma ,ie, bladder cancer. www.nejm.org/doi/full/10.1056/NEJMoa2401726

Pembrolizumab adjuvant immunotherapy after surgery for high risk clear cell renal cell carcinoma improved disease free survival. Now it showed to improve overall survival. www.nejm.org/doi/full/10.1056/NEJMoa2312695

Asciminib was approved for CML chronic phase treatment. www.oncologynewscentral.com/article/fda-grants-accelerated-approval-to-asciminib-for-chronic-myeloid-leukemia

Thankyou sir so much....very well explained.

Could you please answer, my cbc fluctuates 4 months ago my hb was 11.8 and rbc was 4.6 now my hb is 12.8 and rbc are 5.7 my mch is always low. I’m a female

Dr. What food is good for breakfast , lunch and diner for metastasis in liver. My father have metastasis liver. Please help me

I have nsclc stage 3b lung cancer. I see the oncologist tomorrow, I don't know what I'm going to do. I'm really nervous.

Helo sir, My name is sajid Hussain from pakistan. I have high platelets 900 for last three year's. I take medicine hydruxyurea 500mg morning 500 mg night with loprin 75. But not good result. Now doctor told me i have essential thrombocythemia And change medicine now only loprin 75. Now i have back pain and muscles pain .please suggest me what can I do for best.can i take multivitamins or not.please reply me sir please.

❤😊 Thank you so much 🙏

"Ayurveda focuses on treating the root cause, which has made a real difference for my Evans Syndrome symptoms. Planet Ayurveda's products are high quality and well-researched!"

hello doctor! my father has adenocarcinoma having size 7 cm*7.3 cm, in biopsy ck7, ttf 1 and napsin a, declared adenocarcinoma, EGFR mutation not detected, >5% invasive, currently chemotherapy is in progress please guide us what to do further, God bless you

My husband has Been diagnosed with squamous cell carcinoma 3b, T4N2M0 in June 2024, his treatment was delayed until October as he had a pulmonary embolism, he had vats surgery which was unsuccessful 😢he has just had 2nd round today of carboplatin and paclitaxel, they said he has no biomarkers, he is 57 we are totally confused, they said they cannot do radiation either because the tumour is close to his heart, he is due a CT scan in the next 2 weeks, feeling very scared 😢

Updated ASCO Guidelines for HR+, HER2- metastatic breast cancer. One caveat is for For PIK3CA-mutated MBC: Alpelisib in combination with ET should be offered to postmenopausal patients Capivasertib plus endocrine therapy was recommended for patients whose tumors harbor PIK3CA or AKT1 mutations or PTEN inactivation. Patients with PIK3CA mutations can be considered for treatment with alpelisib, but patients with AKT1 mutations should not be. ascopubs.org/doi/10.1200/JCO.21.01392

What an excelent video sir

Thank you for taking the time to explain HCC and treatment options. I'm scheduled to have my biopsy in the morning and this has prepared me for the results and treatment plan.

is this suitable for a patient whose immune system is weak? Or what do you recommend?

FDA OKs Zolbetuximab for Gastric, Gastroesophageal Cancer The FDA has approved zolbetuximab (Vyloy, Astellas Pharma) in combination with fluoropyrimidine and platinum-containing chemotherapy ( FOLFOX or CAPOX) for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma that is claudin 18.2 positive. FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to identify claudin 18.2-positive tumors and thus patients who may be eligible to receive zolbetuximab. Zolbetuximab is the first claudin 18.2-targeting agent approved in the United States. Claudin 18.2 - a cell surface protein prominent in the stomach lining and associated with tumor growth and progression - is overexpressed in about 40% of gastric and gastroesophageal junction tumors. Zolbetuximab binds claudin 18.2 and triggers immune responses that kill the cancer cells. The FDA approval was based on two international phase 3 trials - SPOTLIGHT and GLOW. Across the 565 patients in SPOTLIGHT, adding zolbetuximab to mFOLFOX6 chemotherapy led to a significant improvement in median overall and progression-free survival. Patients who received zolbetuximab with mFOLFOX6 chemotherapy demonstrated a median overall survival benefit of almost 3 months - 18.2 months in the zolbetuximab-chemotherapy arm vs 15.5 months in the chemotherapy-placebo group (hazard ratio [HR], 0.750). Median progression-free survival was 10.6 months in the zolbetuximab plus mFOLFOX6 arm vs 8.7 months in mFOLFOX6 plus placebo arm (HR, 0.751). In GLOW, 507 patients were randomly assigned to either zolbetuximab with CAPOX chemotherapy or placebo with CAPOX. Adding zolbetuximab to CAPOX also led to a significant improvement in overall and progression-free survival. Median overall survival was 14.4 months in the zolbetuximab arm vs 12.2 months in the CAPOX-only group (HR, 0.771), and median progression-free survival was 8.2 months in the zolbetuximab arm vs 6.8 months in the CAPOX-only group (HR, 0.687). The incidence of serious adverse events was similar between the zolbetuximab and placebo arms in both trials. Nausea, vomiting, and decreased appetite were the most common side effects, and were substantially more likely with zolbetuximab add-on. The recommended zolbetuximab dosage with fluoropyrimidine- and platinum-containing chemotherapy is 800 mg/m2 intravenously for the first dose, and 600 mg/m2 intravenously every 3 weeks or 400 mg/m2 intravenously every 2 weeks for subsequent doses.

FDA Approves Inavolisib for HR+, HER2−, Advanced Breast Cancer With PIK3CA Mutation The FDA has approved inavolisib (Itovebi, Genentech) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), locally advanced or metastatic breast cancer following recurrence on or after adjuvant endocrine therapy. The FDA also approved the FoundationOne Liquid CDx assay to identify patients who qualify for the newly approved treatment. The oncogenic PIK3CA mutation is found in approximately 40% HR+ metastatic breast cancers. Novartis' alpelisib (Piqray) also targets the mutation and carries a similar breast cancer indication for combination with fulvestrant. Previous studies showed better efficacy (due to dual blockage of PIK3CA alpha isoform and protein of inavolisib vs. single PIK3CA alpha isoform of alpelisib) and less side effects. Approval of inavolisib was based on the INAVO120 trial, which randomized 325 qualifying patients equally to receive either inavolisib 9 mg or placebo orally once daily on a background of palbociclib and fulvestrant in 28-day treatment cycles. Patients had progressed during or within 12 months of completing adjuvant endocrine therapy and had not received prior systemic therapy for locally advanced or metastatic disease. Median investigator-assessed progression-free survival was 15 months with inavolisib vs 7.3 months with placebo (hazard ratio, 0.43; P < .0001). The objective response rate (ORR) was 58% and median duration of response (DOR) was 18.4 months in the inavolisib arm vs an ORR of 25% and DOR of 9.6 months in the placebo arm. An interim analysis of overall survival did not reach statistical significance but favored inavolisib. The most common adverse reactions with inavolisib, occurring in 20% or more of patients, were decreased neutrophils, hemoglobin, platelets, lymphocytes, calcium, potassium, sodium, magnesium, and appetite; increased fasting glucose, creatinine, and alanine aminotransferase; stomatitis; diarrhea; fatigue; nausea; rash; SARS-CoV-2 infection; and headache. The recommended inavolisib dose is 9 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Pricing information wasn't available at press time; 56 tablets of alpelisib, also administered daily, costs $23,217.11, according to drugs.com.

Any information about ret fusion mutation in metastatic adenocarnimo lung with brain. Mets

Dr Kim I need to see you. I have PAH.

Hello I’m a 44 yr old female. My hemoglobin is 16.3, Hct 50% and total rbc 5.43. Is that normal?

Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer, according to results of a phase 3, randomized, double-blind trial. Domenica Lorusso, MD, PhD, director of Gynecological Oncology at Humanitas San Pio X and professor at Humanitas University, Milan, Italy, presented these findings of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study at the European Society for Medical Oncology (ESMO) Annual Meeting 2024. The results were published online ahead of print in The Lancet on the day of the presentation. "For more than 20 years, the standard treatment of locally advanced cervical cancer has been concurrent chemoradiation plus brachytherapy, based on the results of five randomized trials that reported a 6% increase in overall survival when we combined chemotherapy with radiation," Lorusso said. The study enrolled 1060 patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, defined as FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of the lymph node status. Patients were randomized 1:1 to receive either pembrolizumab or placebo in combination with standard CCRT. Patients in the pembrolizumab arm received 200 mg every 3 weeks for five cycles during CCRT, followed by 400 mg every 6 weeks for 15 cycles. According to Lorusso, the trial is particularly notable for its use of modern radiotherapy techniques. Over 85% patients were treated with intensity-modulated external beam radiotherapy, and a similar proportion received volume-based brachytherapy, she said. The median total equivalent dose in 2-Gy fraction (EQD2 dose) to the high-risk clinical target volume was 87 Gy. R.A. Nout, MD, PhD, professor of radiotherapy at Erasmus MC, Rotterdam, the Netherlands, said giving this dose reflects contemporary best practices in radiation oncology for cervical cancer. At a median follow-up of 29.9 months (range, 12.8-43.0 months), the study met its primary endpoint, demonstrating a statistically significant improvement in overall survival with pembrolizumab plus CCRT vs placebo plus CCRT. The 36-month overall survival rate was 82.6% in the pembrolizumab arm vs 74.8% in the placebo arm (hazard ratio [HR], 0.67; 95% CI, 0.50-0.90; P = .0040). Lorusso emphasized the clinical significance of these results: "A statistically significant and [clinically] meaningful overall survival benefit was reported in patients treated with pembrolizumab, with a hazard ratio of 0.67, suggesting a 33% reduction in the risk of death." The benefit of pembrolizumab was consistent across prespecified subgroups, including FIGO stages IB2-IIB (HR, 0.89; 95% CI, 0.55-1.44) and III-IVA (HR, 0.57; 95% CI, 0.39-0.83). Progression-free survival (PFS), a co-primary endpoint, also showed significant improvement. At 2 years, 67% patients in the pembrolizumab arm were free of progression compared with 57% patients in the placebo arm (HR, 0.65; 95% CI, 0.53-0.79; P < .0001). According to Lorusso, the safety profile of pembrolizumab plus CCRT was manageable and consistent with known toxicities of the individual therapies. Grade ≥ 3 treatment-related adverse events occurred in 69.1% patients in the pembrolizumab group vs 61.3% patients in the placebo group. Immune-related adverse events were more common with pembrolizumab (40% vs 17%) but were mostly grade 1-2. During her talk, Lorusso emphasized that none of the patients experienced colitis. "We pay particular attention to digestive adverse events because of possible overlapping toxicity of immune-related colitis post-radiotherapy colitis," she explained. Commenting on the clinical implications of their findings, Lorusso stated, "In our opinion, these data support pembrolizumab in combination with chemoradiation as the new standard of care in patients with locally advanced high-risk cervical cancer."

You deserve more followers imho.

Should I even worry about Intermediate PMF if I have stage IIIa CRLM?🤔

Will Rusfertide help patients with polycythemia caused from sleep apnea. I have to have a phlebotomy about every 6 weeks.

Patients with sickle cell disease and vaso-occlusive episodes who received lactated Ringer solution had small but significant improvements in outcomes compared with patients who received normal saline. jamanetwork.com/journals/jamainternalmedicine/article-abstract/2823422

Thank you Sir

Durvalumab + platinum chemo as neoadjuvant therapy before NSCLC surgery and adjuvant Durvalumab mono therapy x1 yr was approved by FDA in August 2024. PCR 17% www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer?

Durvalumab neoadjuvant with platinum based chemo q3w x 4 before NSCLC surgery and adjuvant durvalumab mono therapy x 1 yr was approved by FDA in August 2024. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer?

I'll tell everyone about you *MR OBALAR* coming across your TH-cam channel was a blessing, I'm free from hpv, victory at last.

I'll tell everyone about you *MR OBALAR* coming across your TH-cam channel was a blessing, I'm free from hpv, victory at last.

I'll tell everyone about you *MR OBALAR* coming across your TH-cam channel was a blessing, I'm free from hpv, victory at last.

Hello. Dr Kim my brother in law has HCC liver cancer . He went to the Jewish Hospital in Montreal they convinced him to do the treatment, he have water retention in his abdomen and in his legs to his feets, including diabetes. He said it get worst when they did the treatment second time. Last weeks the doctors said the treatment doesn't work and they said its useless if they continue to do the treatment and now for him to decide if he will continue the treatments or he will stop. They said he will not live longer. What upset me doctors there doesn't encouraging him it's like telling him there's no hope for him and he's desperate like waiting the day to end. If i can find someone can cure him i will take him there. Thank you.

Neoadjuvant chemo radiation therapy was not better than neoadjuvant chemotherapy for respectable gastric cancer. It did not improve Overall survival although complete pathological response was higher: 16 vs 8 %. www.nejm.org/doi/full/10.1056/NEJMoa2405195

Glofitamab is the first CD20 x CD3 bispecific antibody to demonstrate an overall survival benefit in DLBCL. A novel treatment regimen with the bispecific antibody glofitamab has demonstrated improvements in survival outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data presented at the European Hematology Association (EHA) 2024 Congress. The phase III STARGLO trial evaluated the efficacy and safety of glofitamab plus gemcitabine and oxaliplatin compared with rituximab plus gemcitabine and oxaliplatin in patients with DLBCL who had received at least one prior line of therapy. The results showed a near doubling of median overall survival and a 38% reduction in the risk of death (hazard ratio [HR] = 0.62, P = .006). Authors of the study noted that the addition of glofitamab to gemcitabine and oxaliplatin may become a new standard of care for patients who have limited treatment options, particularly those who are ineligible for chimeric antigen receptor (CAR) T-cell therapy or autologous stem cell transplantation. “Glofitamab is the first CD20 x CD3 bispecific antibody to demonstrate an overall survival benefit in DLBCL in a randomized phase III trial,”

Thank you very much for your kingly good heart, GBU dokter it is very helpful for my priest friend in indonesia

Capivasertib + endocrine therapy was recently approved for Horome Receptor + HER2- metastatic breast cancer which has + AKT1 or PIK3CA mutation as a second line therapy. ASCO issued a rapid recommendation update, published in the Journal of Clinical Oncology, regarding the use and timing of endocrine and targeted therapies for patients with HR-positive, HER2-negative metastatic breast cancer. The updated recommendations build upon clinical practice guidelines originally published in July 2021. This update was based on results from the CAPItello-291 study, a phase 3 clinical trial evaluating fulvestrant plus capivasertib in patients with metastatic breast cancer. Capivasertib is an AKT pathway inhibitor, and the study included patients with AKT1, PIK3CA, and PTEN alterations. Following results of the study, the FDA approved capivasertib, along with a companion diagnostic, in November 2023. The panel recommended that patients with HR-positive, HER2-negative breast cancer should receive multiple lines of endocrine therapy, usually in combination with targeted therapies. Genomic testing for activating mutations should be regularly performed. CDK4/6 inhibitors should be paired with endocrine therapy in the first line, while second- and third-line therapy should be determined through genomic testing. Capivasertib plus endocrine therapy was recommended for patients whose tumors harbor PIK3CA or AKT1 mutations or PTEN inactivation. Patients with PIK3CA mutations can be considered for treatment with alpelisib, but patients with AKT1 mutations should not be. “There are no comparative efficacy data for choosing a PIK3CA targeted option for those who are potential candidates for capivasertib or alpelisib treatment,” the panelists wrote. “For such patients, the panel recommends selecting the targeted agent based on perceived risk-benefit considerations such as hyperglycemia, diarrhea, or treatment discontinuation for adverse events.” The panel noted that grade 3 diarrhea and rash occurred more commonly with capivasertib (9.3% vs 6.7% and 12.1% vs 9.9%, respectively) but that hyperglycemia was more common among patients treated with alpelisib (36.6% vs 2.3%). Antihistamines, anti-diarrheal agents, and supportive care measures can be employed to mitigate potential symptoms caused by these adverse events. Everolimus can be considered for all patients regardless of tumor genomics. Monotherapy with elacestrant can be considered for patients with tumors harboring an ESR1 mutation. “While newer agents have been added to the armamentarium, there remain few studies on the optimal timing or sequence of treatments, comparisons of targeted agents within a class, or studies that compare one class of agents against another,” the panel concluded. “Such trials are an important clinical priority, as are studies to mitigate side effects of these agents.”